No abstract available
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Biological Therapy / adverse effects*
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Capecitabine
-
Cetuximab
-
Clinical Trials as Topic
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / mortality
-
Colorectal Neoplasms / pathology
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Disease Progression
-
ErbB Receptors / drug effects
-
ErbB Receptors / metabolism
-
Fluorouracil / administration & dosage
-
Fluorouracil / analogs & derivatives
-
Humans
-
Leucovorin / administration & dosage
-
Organoplatinum Compounds / administration & dosage
-
Oxaliplatin
-
Panitumumab
-
Survival Analysis
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Organoplatinum Compounds
-
Oxaliplatin
-
Deoxycytidine
-
Bevacizumab
-
Capecitabine
-
Panitumumab
-
ErbB Receptors
-
Cetuximab
-
Leucovorin
-
Fluorouracil
-
Camptothecin
Supplementary concepts
-
Folfox protocol
-
IFL protocol